Compare Cytokinetics Inc (CYTK) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Stanley Black & Decker, Inc. — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Stanley Black & Decker, Inc. trades at $88.68 (market cap $13.47B). The key difference: Stanley Black & Decker, Inc. is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| CYTK | SWK | |
|---|---|---|
Market Cap | $8.62B | $13.47B |
Volume | 2,594,626 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $87.26 | $104.00 |
52-Week Low | $54.76 | $62.12 |
Typical Hold Time | 19 Days | 62 Days |
Enterprise Value | $8.72B | $17.63B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
Stanley Black & Decker (SWK) trades at $88.57, up 0.29% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin of 4.06%. Valuation appears reasonable with P/E of 21.8 and P/S of 0.89. Recent product launches include the dustbuster mini vacuum, while management focuses on margin improvement and DEWALT market share gains.
SWK presents a mixed outlook with analyst consensus at $93.00 (5% upside) but technical indicators signaling caution. The company's dividend king status provides income stability, though operational execution risks and competitive pressures remain concerns. Near-term catalyst includes Q3 2026 earnings release on November 4, 2026, which could validate margin improvement progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
